EGFR and non-small cell lung carcinoma: Notably, 70% (7/10) of these patients possessed longer iPFS (> 110 days), which indicates that RT alone or a combination of EGFR-TKIs with RT might effectively reduce or eliminate EGFR-TKIs resistant clones in BMs from NSCLC.